Simultaneous pancreas–kidney transplantation in patients with type 1 diabetes reverses elevated MBL levels in association with MBL2 genotype and VEGF expression by Roel Bijkerk et al.
ARTICLE
Simultaneous pancreas–kidney transplantation in patients
with type 1 diabetes reverses elevated MBL levels in association
withMBL2 genotype and VEGF expression
Roel Bijkerk1,4 & Pieter van der Pol1 & Meriem Khairoun1 &
Danielle J. van Gijlswijk-Jansen1 & Ellen Lievers1 & Aiko P. J. de Vries1 &
Eelco J. de Koning1 & Hans W. de Fijter1 & Dave L. Roelen2 & Rolf H. A. M. Vossen3 &
Anton Jan van Zonneveld1,4 & Cees van Kooten1 & Marlies E. J. Reinders1
Received: 8 September 2015 /Accepted: 14 December 2015
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Aims/hypothesis High levels of circulating mannan-binding
lectin (MBL) are associated with the development of diabetic
nephropathy and hyperglycaemia-induced vasculopathy.
Here, we aimed to assess the effect of glycaemic control on
circulating levels of MBL and the relationship of these levels
with vascular damage.
Methods We assessed MBL levels and corresponding MBL2
genotype, together with vascular endothelial growth factor
(VEGF) levels as a marker of vascular damage, in type 1
diabetes patients with diabetic nephropathy before and after
simultaneous pancreas–kidney (SPK) transplantation. We in-
cluded diabetic nephropathy patients (n=21), SPK patients
(n=37), healthy controls (n=19), type 1 diabetes patients
(n=15) and diabetic nephropathy patients receiving only a
kidney transplant (n= 15). Fourteen diabetic nephropathy
patients were followed up for 12 months after SPK.
Results We found elevated circulating MBL levels in diabetic
nephropathy patients, and a trend towards elevated circulating
MBL levels in type 1 diabetes patients, compared with healthy
control individuals. MBL levels in SPK patients completely
normalised and our data indicate that this predominantly
occurs in patients with a polymorphism in the MBL2 gene.
By contrast, MBL levels in kidney transplant only patients
remained elevated, suggesting that glycaemic control but not
reversal of renal failure is associated with decreased MBL
levels. In line, levels of glucose and HbA1c, but not creatinine
levels and estimated GFR, were correlated with MBL levels.
VEGF levels were associated with levels of MBL and HbA1c
in an MBL-polymorphism-dependent manner.
Conclusions/interpretation Taken together, circulating MBL
levels are associated with diabetic nephropathy and are
dependent on glycaemic control, possibly in an MBL2-
genotype-dependent manner.
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Introduction
High levels of circulating mannan-binding lectin (MBL) have
been demonstrated to be associated with the clinical
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manifestation of type 1 diabetes [1] and the development of
diabetic nephropathy [2]. MBL is an essential component
of the innate immune response; the protein is the major
recognition molecule of the lectin pathway of complement
activation and is activated by binding sugar moieties [3].
Enhanced glycation results in increased MBL activity and
the subsequent activation of the complement system [4] and
high levels of cytokines specific to type 1 diabetes [5].
Specific single nucleotide polymorphisms (SNPs) in the
MBL2 gene and promoter region result in inter-individual
variations in circulating levels of functional MBL
(0–4,000 μg/l). The effect of different MBL2 genotypes on
the risk of developing diabetic nephropathy is unclear as some
studies have reported that individuals with high-producing
MBL2 genotypes have an increased risk of developing
nephropathy [6], whereas others have found that genotype
variations do not confer risk of diabetic nephropathy [7].
In a model of type 1 diabetes in mice, MBL deficiency
attenuates renal changes [8]. Furthermore, diabetes mellitus
is strongly associated with microvascular complications
(including retinopathy, neuropathy and nephropathy), and
vasculopathy resulting from hyperglycaemia has been shown
to be dependent on MBL and lectin complement pathway
activation [9].
Simultaneous pancreas–kidney (SPK) transplantation is an
advanced treatment option for type 1 diabetic patients with
diabetic nephropathy and we previously demonstrated that
microvascular damage is reversed in the first year after SPK
[10]. Here, we studied this cohort of healthy control
participants and type 1 diabetes patients before and following
SPK or kidney transplantation alone to investigate the
relationship between circulating MBL and vascular endothe-
lial growth factor (VEGF) levels, and how glycaemic control
and MBL2 genotype influence their levels.
Methods
Patients and design All procedures were approved by the
institution’s Medical Ethical Committee and written informed
consent was obtained from all patients and control
participants.
Details of the cohort have previously been described
[10, 11] and are presented in Table 1. In short, 107 patients
were enrolled in an observational, cross-sectional study that
consisted of five groups: (1) a control group (n=19) of healthy
volunteers; (2) type 1 diabetic patients with an estimated GFR
(eGFR) of ≥30 ml min−1 1.73 m−2 (n=15); (3) type 1 diabetic
patients with diabetic nephropathy (n = 21); (4) diabetic
nephropathy patients with a functioning kidney graft after
kidney transplantation (KTx, n=15); and (5) patients who
received SPK in the past (n=37). Inclusion and exclusion
criteria were previously described [10].
In a longitudinal study (Table 2), diabetic nephropathy
patients who received SPK were followed up (n=14): plasma
samples were obtained before (D0) and 1 month (M1),
6 months (M6) and 12 months (M12) after SPK.
All transplantations were performed at the Leiden Univer-
sity Medical Center in the Netherlands. Transplantation pro-
cedures have previously been described [10]. Immunosup-
pressive therapies consisted of induction therapy followed
bymaintenance therapy, as previously described and indicated
in Tables 1 and 2.
Clinical variables All patients and controls underwent rou-
tine venous blood sampling in the morning before intake of
immunosuppression. Creatinine, haemoglobin, HbA1c, glu-
cose, proteinuria in 24 h urine and urea were measured.
GFR was calculated with plasma creatinine concentration
using the Modification of Diet in Renal Disease (MDRD)
formula. Plasma was harvested by centrifugation of EDTA-
anticoagulated blood for 10 min at 1,000g and subsequently
stored at −80°C for VEGF and −20°C forMBL determination.
MBL2 genotypingDNAwas isolated from peripheral EDTA-
anticoagulated blood. SNPs at codons 52 (D allele), 54 (B
allele) and 57 (C allele) of theMBL2 gene and in the promoter
region were determined by high resolution melting analysis as
previously described [12]. The ‘wild-type’ genotype is named
A/A and the presence of 1 or 2 variant alleles(s) containing
SNPs (B, C or D) are named A/O or O/O, respectively. The
promoter region SNP, which results in reduced MBL2 gene
expression, has been named P.
Plasma MBL and VEGF levels Plasma MBL levels were
assessed by ELISA as previously described [13]. VEGF levels
were determined by ELISA (Diaclone Research, Besançon,
France) according to the instructions of the manufacturer.
Statistical analyses In Table 1, parametric data are presented
as mean±SD. Nonparametric data are shown as median and
interquartile range (IQR) and tested with one-way ANOVA
(Tukey post hoc test). Categorical variables were analysed
with Fishers exact test. The longitudinal study was analysed
with repeated measures analysis. Differences between cate-
gorical data have been computed using Friedman’s 2-way
ANOVA by ranks. Differences between MBL levels were
adjusted for sex, age and duration of diabetes. Correlations
were calculated using Pearson correlation. A p value <0.05
was considered to be statistically significant. Data analysis
was performed using SPSS version 20.0 (SPSS, Chicago,
IL, USA) and GraphPad Prism, version 5.0 (GraphPad Prism
Software, San Diego, CA, USA).
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Results
Circulating levels of MBL associate with diabetic ne-
phropathyWe first sought to determine whether diabetic ne-
phropathy patients displayed differential levels of circulating
MBL. As shown in Fig. 1a, diabetic nephropathy patients
have significantly higher plasma MBL levels than healthy
controls (p=0.02) and a trend towards higher levels than type
1 diabetic patients with good renal function.
Diabetic-nephropathy-associated circulating MBL levels
normalise after SPK, but not after kidney transplantation
alone Given that SPK makes the patients normoglycaemic
and restores kidney function, we sought to determine whether
Table 1 Cross-sectional study patient characteristics
Controls (n = 19) DM ≥30 ml min−1
1.73 m−2 (n= 15)
DN (n = 21) SPK (n = 37) KTx (n= 15)
Sex, male, n (%) 9 (47%) 6 (40%) 16 (76%) 24 (65%) 6 (40%)
Age (years) 44 ± 11 55± 13* 44± 5† 48 ± 8 48± 10
BMI (kg/m2) 25.2 ± 3.8 23.8 ± 2.8 25.4 ± 3.2 24.3 ± 4.4 25.0 ± 4.6
HbA1c (%) (mmol/mol) – 7.1 ± 0.7 (54 ± 7.7) 8.9 ± 2.3
† (74 ± 25.1) 5.6 ± 0.8†,‡ (38 ± 8.7) 8.5 ± 0.9†,§ (69 ± 9.8)
Glucose (mmol/l) 5.3 ± 1.0 12.8 ± 4.7* 13.8 ± 6.4* 6.0 ± 2.9†,‡ 13.0 ± 6.7*,§
eGFR (ml min−1 1.73 m−2) 93 ± 17 70± 24* 18± 7*,† 53 ± 19*,†,‡ 62± 23*,‡
Median proteinuria (g/24 h) (IQR) – 0.29 (0.13–0.29) 0.72 (0.35–1.5) 0.27 (0.17–0.82)‡ 0.21 (0.18–0.36)‡
Systolic blood pressure (mmHg) 131 ± 12 130 ± 13 146 ± 19 139 ± 23 138 ± 29
Diastolic blood pressure (mmHg) 82± 7 71± 8* 86± 11† 83 ± 13† 81± 14
Haemoglobin (mmol/l) 8.7 ± 0.7 8.2 ± 1.3 7.6 ± 0.5* 8.1 ± 1.2 8.2 ± 1.1
Haematocrit (l/l) 0.41 ± 0.03 0.40± 0.05 0.36± 0.03* 0.40± 0.05‡ 0.41± 0.05‡
Duration of diabetes (years) – 35± 10 29± 9 27 ± 8† 35± 9§
Dialysis, n (%) – 0 (0%) 3 (14%) 0 (0%)‡ 0 (0%)
Median time since KTx or SPK
(months) (IQR)
– – – 45 (19–110) 21 (9–69)
Rejection after KTx or SPK, n (%) – – – 13 (35%) 0 (0%)
Diabetes after SPK, n (%) – – – 3 (8%) –
Smoking, n (%) 0 (0%) 2 (13%) 0 (0%) 3 (8%) 1 (7%)
Acetylsalicylic acid, n (%) – 3 (20%) 2 (10%) 11 (30%) 3 (20%)
Antihypertensive drugs, n (%) –
ACE inhibitor 7 (47%) 14 (67%) 14 (38%) 7 (47%)
Angiotensin-II antagonist 3 (20%) 13 (62%)† 8 (22%)‡ 0 (0%)‡
Calcium antagonist 2 (13%) 11 (52%)† 22 (60%)† 7 (47%)
Diuretic 5 (33%) 13 (62%) 9 (24%)‡ 4 (27%)‡
β-Blocker 0 (0%) 9 (43%)† 19 (51%)† 6 (40%)†
Statin, n (%) – 8 (53%) 13 (62%) 26 (70%) 5 (33%)
Steroid-free, alemtuzumab induction,
n (%)
– – – 12 (32%) 1 (7%)
Immunosuppressive drugs, n (%) – – –
Cyclosporine 13 (35%) 1 (7%)§
Tacrolimus 24 (65%) 11 (73%)
Prednisone 26 (70%) 9 (60%)
Azathioprine 3 (8%) 0 (0%)
Sirolimus 0 (0%) 1 (7%)
Everolimus 2 (5%) 0 (0%)
Mycophenolate mofetil 27 (73%) 14 (93%)
Parametric data are presented as mean± SD. Nonparametric data are presented as median and IQR. Categorical data are presented as frequency and
percentage
*p< 0.05 vs controls; † p< 0.05 vs DM ≥30 ml min−1 1.73 m−2 ; ‡ p< 0.05 vs DN; § p< 0.05 vs SPK
ACE, angiotensin-converting enzyme
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this would affect plasma MBL levels. As depicted in Fig. 1a,
we observed that SPK normalised plasma MBL levels. In
addition, we determined whether kidney transplantation alone
would affect MBL levels. Interestingly, this did not alter MBL
levels (Fig. 1a), suggesting that normoglycaemia is responsi-
ble for normalisation of MBL levels. Figure 1b illustrates av-
erage MBL levels among all patient groups. MBL significant-
ly correlates with both levels of glucose (p=0.005; r=0.31)
and HbA1c (p=0.02; r=0.25), and also with duration of dia-
betes (p=0.01; r=−0.26) and age (p=0.006; r=−0.29). By
contrast, we did not find significant correlations with creati-
nine levels and eGFR, or with proteinuria, retinopathy, neu-
ropathy or cardiovascular events (data not shown).
MBL2 genotype affects normalisation of MBL levels after
SPK To investigate whether a specific MBL2 genotype
associated with SPK-mediated normalisation of circulating
MBL levels, polymorphisms of theMBL2 exon 1 and promot-
er were determined. We separated the patient groups per poly-
morphism and displayed the corresponding MBL levels
(Fig. 1c), which illustrated that normalisation of MBL levels
after SPK was particularly observed in patients with an MBL
polymorphism, whereas it was less obvious in ‘wild-type’
MBL carriers.
Longitudinal study shows a trend towards normalisation
of MBL levels after SPK Given that MBL levels show
considerable variation among individuals, which compli-
cates the interpretation of MBL differences, we next
sought to determine if we could validate the normalisa-
tion of MBL levels in patients who were followed up
Table 2 Follow-up study patient characteristics
D0 (n= 14) M1 (n= 14) M6 (n = 14) M12 (n= 14)
Sex, male, n (%) 13 (93%) – – –
Age (years) 45.1 ± 5.2 – – –
BMI (kg/m2) 26.0 ± 2.8 24.7 ± 2.9 24.7 ± 2.1 24.8 ± 2.5
HbA1c (%) (mmol/mol) 8.8 ± 1.7 (73 ± 18.6) 6.5 ± 1.8* (48± 19.7) 5.3 ± 0.3* (34 ± 3.3) 5.4 ± 0.2* (36 ± 2.2)
Glucose (mmol/l) 14.7 ± 7.1 6.3 ± 1.0* 5.3 ± 1.4* 5.8 ± 1.5*
eGFR (ml min−1 1.73 m−2) 18 ± 9 54 ± 19* 54± 15* 54± 11*
Median proteinuria (g/24 h) (IQR) 0.73 (0.36–1.30) 0.66 (0.28–1.15) 0.41 (0.17–0.98) 0.37 (0.14–1.10)
Systolic blood pressure (mmHg) 153 ± 15 129 ± 21* 133 ± 20* 131 ± 14*
Diastolic blood pressure (mmHg) 87± 11 78 ± 11 78± 11 78± 6
Haemoglobin (mmol/l) 7.6 ± 0.5 6.6 ± 0.9* 7.4 ± 0.9 8.0 ± 1.0
Haematocrit (l/l) 0.37 ± 0.03 0.33± 0.05 0.37± 0.04 0.40 ± 0.05
Diabetes after SPK, n (%) – 1 (7%) 2 (14%) 0 (0%)
Smoking, n (%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Acetylsalicylic acid, n (%) 3 (21%) 1 (7%) 1 (7%) 4 (29%)
Antihypertensive drugs, n (%)
ACE inhibitor 9 (64%) 2 (14%)* 3 (21%)* 3 (21%)*
Angiotensin-II antagonist 9 (64%) 1 (0%) 1 (0%) 1 (0%)
Calcium antagonist 8 (57%) 4 (29%) 5 (36%) 8 (57%)
Diuretic 10 (71%) 1 (0%) 1 (7%)* 2 (14%)*
β-Blocker 8 (57%) 6 (43%) 4 (29%) 4 (29%)
Statin, n (%) 8 (57%) 2 (14%)* 2 (14%)* 3 (21%)*
Steroid-free, alemtuzumab induction, n (%) – 14 (100%) – –
Immunosuppressive drugs, n (%) –
Cyclosporine 1 (7%) 2 (14%) 1 (7%)
Tacrolimus 12 (86%) 11 (79%) 11 (79%)
Prednisone 1 (7%) 4 (29%)† 4 (29%)†
Everolimus 1 (7%) 1 (7%) 2 (14%)
Mycophenolate mofetil 14 (100%) 13 (93%) 14 (100%)
Parametric data are presented as mean± SD. Nonparametric data are presented as median and IQR. Categorical data are presented as frequency and
percentage
*p< 0.05 vs D0; † p< 0.05 vs M1
ACE, angiotensin-converting enzyme; D0, before transplantation; M1, M6 and M12, 1, 6 and 12 months post-transplantation, respectively
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after SPK. Although SPK seems to cause an initial in-
crease in MBL levels at M1, 12 months after SPK we
found a trend towards decreased plasma MBL levels
(Fig. 1d).
MBL levels associate with VEGF levels in a polymorphism-
dependent manner When patients were divided into wild-
type MBL and MBL polymorphism groups, it was clear that
VEGF levels increased after SPK in patients with an MBL
polymorphism (Fig. 1e). This separation of MBL2 genotypes
also revealed a correlation of HbA1c with VEGF levels (data
not shown): in wild-type MBL carriers we observed a positive
correlation, while in MBL polymorphism carriers there was a
negative correlation. No MBL2-genotype-dependent
correlations were observed with proteinuria, retinopathy, neu-
ropathy or cardiovascular events.
Discussion
In this study, we have shown an elevation of plasma MBL
levels in patients with diabetic nephropathy, which normalises
after SPK. Kidney transplantation alone does not result in a
decrease in MBL levels, suggesting that this normalisation is
dependent on glycaemic control.
Our data suggest that predominantly patients with an
MBL polymorphism have normalised levels of MBL after
SPK. Interestingly, low pretransplantation MBL levels
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Fig. 1 SPK in patients with type 1 diabetes reverses elevatedMBL levels
in association with MBL2 genotype and VEGF expression. (a) Circulat-
ing MBL levels are increased in diabetic nephropathy (DN) patients and
normalise after SPK. (b) Data in (a) presented as a bar graph. (c) Subdi-
vision of polymorphisms per patient group suggests that predominantly
patients with a polymorphism in the MBL2 gene show normalisation of
MBL levels after SPK. The scale is presented as a log10 scale. For an
explanation of the different genotypes please refer to the ‘MBL2 genotyp-
ing’ section of the Methods. (d) Circulating MBL levels in DN patients
who received SPK and were followed up longitudinally before transplan-
tation (D0), and 1, 6 and 12 months (M) after SPK. (e) VEGF levels
plotted for DN and SPK groups divided by patients with wild-type
MBL or MBL polymorphism carriers. *p< 0.05. Data are presented as
mean + SEM. Co, control groups of healthy volunteers; DM, type 1 dia-
betes patients with an eGFR of ≥30 ml min−1 1.73 m−2; DN, type 1
diabetic patients with diabetic nephropathy; KTx, diabetic nephropathy
patients with a functioning kidney graft; SPK, patients who received SPK
in the past
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survival after SPK [13]. Although speculative, our data
suggest a link between high MBL levels and the lack of
capacity to lower MBL levels after transplantation. We
also found a relationship between MBL levels and circu-
lating VEGF levels. Surprisingly, this correlation was pos-
itive in wild-type MBL carriers and negative in patients
with an MBL polymorphism. A similar correlation was
observed for VEGF with HbA1c levels. Although
(podocyte-derived) VEGF is usually considered to medi-
ate the development of diabetic nephropathy [14], it has
also been described that VEGF can be protective in dia-
betic nephropathy [15], providing a possible explanation
for ‘better’ normalisation after SPK in patients with an
MBL polymorphism. However, as group sizes were lim-
ited in our study, these observations need confirmation in
larger patient cohorts.
In the longitudinal study, we observed a trend towards de-
creased MBL levels 12 months after SPK that would confirm
the effect of SPK on MBL in patients in a controlled cohort
with similar immunosuppressive drugs. This decrease was not
as strong as we observed in the cross-sectional cohort. How-
ever, 12 out of 14 patients in the longitudinal study were wild-
type MBL carriers (data not shown), which we, in the cross-
sectional study, found to associate with only a modest de-
crease in MBL levels after SPK.
We cannot exclude that the use of immunosuppression after
transplantation influenced the normalisation of MBL levels
after SPK in our study. Nonetheless, this seems unlikely be-
cause patients in the KTx group also received immunosup-
pressive drugs but did not show decreased levels of MBL.
Taken together, we have demonstrated that circulating
levels of MBL are elevated in diabetic nephropathy patients
and normalised after SPK. The normalisation of MBL levels
was independent of renal function, but dependent on
glycaemic control, and might only occur in patients with a
polymorphism in MBL, which could affect the development
of vascular injury.
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